New insights into PSAT1 as a therapeutic target for myelodysplastic syndrome (MDS).

ABSTRACT: The metabolomic landscape in myelodysplastic syndrome (MDS) is highly deregulated and presents promising avenues for understanding disease pathogenesis and potential molecular dependencies. Here, we evaluated the transcriptomic landscape in MDS in multiple independent studies focusing more on metabolomics pathways. Identifying molecular dependencies will pave the way for a more precise disease stratification as well as the development of novel personalized treatment strategies. The study adopted a retrospective, cross-sectional approach, utilizing transcriptomic data from multiple MDS studies. The transcriptomic data were then subjected to comprehensive analyses, including differential gene expression, gene enrichment analysis, gene co-expression analysis, protein-protein interaction analy

SUBMITTER: Alatawi S 

PROVIDER: S-EPMC11346733 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature